Medical device maker Insulet's new collaboration with Pantone aims to shift sentiment. Here's why it may work.
Zacks Investment Research on MSN
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
Insulet PODD has seen impressive momentum in the past year, with its shares soaring 37.4%. It has significantly outperformed the industry’s 0.5% fall and the S&P 500 composite’s 17.5% gain. Presently ...
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...
Patients with type 2 diabetes who used the Omnipod 5 had lower A1C after 8 weeks. Those who had been using multiple daily injections achieved the greatest benefits in reduced hypoglycemia and reduced ...
ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” second-quarter 2025 ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
The way we move from A to B in cities and beyond is changing. We're not only seeing automakers commit to an electric future, but also investing in autonomous driving technologies. Electronics giant LG ...
Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback